STAT Plus: Innovent starts China’s first trial of a novel cancer immunotherapy
A version of this story appeared Tuesday in STAT China, a weekly guide to biopharma and life sciences news in China. Sign up here to receive it in your inbox.
Cancer drug developer Innovent Biologics started an early-stage clinical trial for its monoclonal antibody IBI939, the first anti-TIGIT drug to be tested in China.
